Neurim Pharmaceuticals

What Neurim Pharmaceuticals does

Neurim Pharmaceuticals (1991) Ltd. is a privately held, founder-led CNS-focused drug discovery and development company headquartered in Tel Aviv, Israel, with a Swiss subsidiary in Steinhausen. Founded in 1991 by neuroscientist Prof. Nava Zisapel and entrepreneur Yehuda Zisapel, the company has built a franchise around melatonin-receptor biology and proprietary prolonged-release melatonin formulations, supported by a portfolio of over 60 patents and 200+ peer-reviewed publications. Its two commercialized ethical drugs are Circadin® (2mg prolonged-release melatonin, EMA-approved in 2007 for primary insomnia in patients aged 55 and older) and Slenyto® (1mg/5mg prolonged-release melatonin mini-tablets, EMA-approved in 2018 for insomnia in children and adolescents with Autism Spectrum Disorder and/or neurogenetic disorders, and indicated in ADHD where sleep hygiene has been insufficient).

The business model is a partner-driven specialty pharma model: Neurim does not sell directly. It out-licenses Circadin and Slenyto to regional marketing and distribution partners (for example, an exclusive licensing and distribution agreement with KYE Pharmaceuticals for Canada following Health Canada approval of Slenyto in September 2025) and earns revenue through licensing fees, milestone payments, and royalties. Products are commercially available in more than 40 countries across 5 continents, and Neurim also runs a development pipeline (Piromelatine for REM Sleep Behavior Disorder/neurodegenerative disease, Neu-4752 for sleep apnea, Neu-6142 for ASD, Neu-601 for Parkinson's, Neu-14E for fibrosis) and pursues co-development partnerships. R&D leadership is concentrated in Prof. Nava Zisapel (CEO and principal inventor) and Dr. Tali Nir (VP Clinical and Regulatory since 1997), with commercial and finance functions strengthened since 2023–2024 by the additions of CFO Nitza Lifshitz and VP Commercial Operations Guy Manor.

Name

Neurim Pharmaceuticals

Legal name

Neurim Pharmaceuticals (1991) Ltd.

Website

https://neurim.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Neurim Pharmaceuticals is a privately held, Israel-based CNS drug discovery company marketing Circadin and Slenyto prolonged-release melatonin products in 40+ countries for insomnia in older adults and pediatric patients with neurodevelopmental disorders, and developing a six-asset neurology pipeline.

Ownership category

akta.pro rank

Product category

CNS Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• CNS pharmaceuticals
• Melatonin therapeutics
• Prolonged-release formulations
• Insomnia treatments
• Pediatric neurology drugs

Headquarters

HQ city

Tel Aviv-yafo

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of proprietary prescription pharmaceutical products including Circadin and Slenyto. Products are marketed through strategic alliances with marketing and distribution partners in over 40 countries.
2. Licensing and Distribution Partnerships: Revenue generated through licensing agreements with distribution partners such as KYE Pharmaceuticals for Canadian market. Partner handles regulatory, commercialization, and distribution activities while Neurim receives licensing fees and royalties.
3. Co-development Partnerships: Strategic collaborations for CNS drug co-development, sharing knowledge and resources with partners in pharmaceutical development and commercialization.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Neurim Pharmaceuticals is a CNS-focused drug discovery and development company that discovers, develops, and commercializes proprietary prescription pharmaceutical products based on prolonged-release melatonin and related CNS compounds. Its two marketed products are Circadin (2mg prolonged-release melatonin for primary insomnia in adults aged 55+) and Slenyto (1mg/5mg prolonged-release melatonin mini-tablets for pediatric insomnia associated with Autism Spectrum Disorder and neurogenetic disorders), which are out-licensed and distributed through strategic marketing and distribution partners in more than 40 countries across five continents.

Product overview

Neurim Pharmaceuticals is a CNS-focused pharmaceutical company with two marketed prescription drugs: Circadin (2mg prolonged-release melatonin for primary insomnia in adults 55+) and Slenyto (1mg/5mg prolonged-release melatonin for pediatric insomnia in ASD, neurogenetic disorders, and ADHD). Both are melatonin-based products marketed in over 40 countries. The company pipeline includes six investigational candidates targeting REM Sleep Behavioral Disorder (Piromelatine), metabolic disorders (Neu-4752), Autism Spectrum Disorder (Neu-6142), Parkinson's disease (Neu-601), and fibrosis (Neu-14E).

Differentiator

Problem solved

Functional benefit

Products and services

• Circadin Circadin is a 2mg prolonged-release melatonin tablet approved for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 years and older. It is an ethical prescription drug distributed in over 40 countries.
• Slenyto Slenyto is a 3mm diameter film-coated mini-tablet containing prolonged-release melatonin (1mg or 5mg). It is the first and only prescription extended-release melatonin specifically developed for treating insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder and/or neurogenetic disorders, and aged 6-17 with ADHD where sleep hygiene measures have been insufficient.

Quantifiable outcome

• Products are in use in more than 40 countries across 5 continents
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• KYE Pharmaceuticals Inc.coreChannel Partner/ Reseller/ Distributor · 13 January 2026Exclusive licensing and distribution agreement for Slenyto (extended-release melatonin) in Canada. KYE Pharmaceuticals handles all regulatory, commercialization, and distribution activities for Slenyto in Canada. Slenyto received Health Canada marketing authorization on September 8th, 2025. The partnership aligns with KYE's mission to bring differentiated therapies to patients with high unmet medical needs in Canada.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Avadel Pharmaceuticals: Specialty pharma built around a single sleep-disorder product (Lumryz for narcolepsy). Comparable as a small, sleep-focused company whose value is anchored by one differentiated therapeutic and a focused commercial strategy.
• Idorsia Pharmaceutical: Swiss CNS-focused specialty pharma with a portfolio centered on sleep and neurology (e.g., Quviviq for insomnia). Comparable as a CNS/sleep-focused, mid-sized specialty pharma with a small but focused commercial organization.
• Neuraxpharm: European specialty pharmaceutical company exclusively focused on CNS disorders, with a portfolio spanning sleep, neurology, and psychiatry. Closely comparable business model: CNS-niche branded specialty pharma selling through partners and direct channels in Europe.
• Vanda Pharmaceuticals: Small US specialty pharma focused on CNS and sleep disorders (e.g., Hetlioz for non-24 sleep-wake disorder). Directly comparable as a small, CNS-focused, sleep-medicine company with a small headcount and one or two core commercial assets.

Broad incumbents

• UCB: Global biopharma with a substantial CNS franchise (e.g., Keppra, Briviact in neurology and psychiatry). Comparable in CNS focus and branded specialty pharma orientation, though at much larger scale and broader therapeutic scope.
• Jazz Pharmaceuticals: Established specialty pharma with a major sleep-medicine franchise (Xywav/Xyrem for narcolepsy, Sunosi for excessive daytime sleepiness) and broader CNS focus. Comparable as a CNS/sleep specialist with multiple approved products, though at meaningfully larger scale.
• Takeda Pharmaceutical: Global pharma with CNS products including Rozerem (ramelteon), a melatonin receptor agonist for insomnia. Comparable in the insomnia / melatonin-receptor therapeutic category, though as part of a much broader portfolio.
• Otsuka Pharmaceutical: Major Japanese pharma with a strong CNS portfolio (e.g., Abilify in psychiatry, investigational CNS assets). Comparable in CNS development and commercialization, but at substantially greater scale and broader therapeutic footprint.
• H. Lundbeck: Large European specialty pharma dedicated to CNS, including sleep and neurology. Comparable in therapeutic focus (CNS/neurology) but at significantly greater scale and broader portfolio than Neurim.

Emerging players

• Biocodex: French independent specialty pharma active in CNS and rare diseases, and a known distribution partner for Circadin in certain markets. Comparable as an independent specialty CNS company, with overlap in pediatric and CNS therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurim-pharmaceuticals-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurim Pharmaceuticals